The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo - PubMed (original) (raw)
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
Eric Sanchez et al. Leuk Res. 2011 Mar.
Abstract
Panobinostat (LBH589) is a potent histone deacetylase inhibitor (HDACi) that has shown anti-tumor activity in preclinical studies in both solid and hematological malignancies. We evaluated the anti-multiple myeloma (MM) effects of LBH589 alone and with melphalan or doxorubicin using MM cell lines and our human MM xenograft model LAGλ-1. LBH589 treatment resulted in increased acetylation of histones, induction of caspase cleavage, inhibition of cell proliferation and synergistic anti-MM effects with melphalan or doxorubicin in vitro. LBH589 with melphalan or doxorubicin also showed significantly enhanced anti-myeloma activity in vivo. These findings provide the basis for clinical development of these combination therapies.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Comment in
Similar articles
- The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutiérrez N, Atadja P, Pandiella A, San Miguel JF. Maiso P, et al. Cancer Res. 2006 Jun 1;66(11):5781-9. doi: 10.1158/0008-5472.CAN-05-4186. Cancer Res. 2006. PMID: 16740717 - Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M, Lamottke B, Mieth M, Jensen MR, Quadt C, Garcia-Echeverria C, Atadja P, Heider U, von Metzler I, Türkmen S, Sezer O. Kaiser M, et al. Eur J Haematol. 2010 Apr;84(4):337-44. doi: 10.1111/j.1600-0609.2009.01403.x. Epub 2009 Dec 17. Eur J Haematol. 2010. PMID: 20028416 - Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR. Campbell RA, et al. Eur J Haematol. 2010 Mar;84(3):201-11. doi: 10.1111/j.1600-0609.2009.01384.x. Epub 2009 Nov 18. Eur J Haematol. 2010. PMID: 19929977 - Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
Atadja P. Atadja P. Cancer Lett. 2009 Aug 8;280(2):233-41. doi: 10.1016/j.canlet.2009.02.019. Epub 2009 Apr 2. Cancer Lett. 2009. PMID: 19344997 Review. - Panobinostat for the treatment of multiple myeloma.
Neri P, Bahlis NJ, Lonial S. Neri P, et al. Expert Opin Investig Drugs. 2012 May;21(5):733-47. doi: 10.1517/13543784.2012.668883. Epub 2012 Mar 12. Expert Opin Investig Drugs. 2012. PMID: 22404247 Review.
Cited by
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N. Santo L, et al. Blood. 2012 Mar 15;119(11):2579-89. doi: 10.1182/blood-2011-10-387365. Epub 2012 Jan 19. Blood. 2012. PMID: 22262760 Free PMC article. - Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies.
Mustafa N, Azaman MI, Ng GGK, Chng WJ. Mustafa N, et al. Biomolecules. 2022 Sep 8;12(9):1261. doi: 10.3390/biom12091261. Biomolecules. 2022. PMID: 36139103 Free PMC article. Review. - Inhibition of Plk1 and Cyclin B1 expression results in panobinostat-induced G₂ delay and mitotic defects.
Prystowsky M, Feeney K, Kawachi N, Montagna C, Willmott M, Wasson C, Antkowiak M, Loudig O, Parish J. Prystowsky M, et al. Sci Rep. 2013;3:2640. doi: 10.1038/srep02640. Sci Rep. 2013. PMID: 24026482 Free PMC article. - Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG. Stessman HA, et al. Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27. Mol Cancer Ther. 2013. PMID: 23536725 Free PMC article. - The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma.
Gkotzamanidou M, Terpos E, Dimopoulos MA, Souliotis VL. Gkotzamanidou M, et al. Int J Mol Sci. 2022 Dec 10;23(24):15671. doi: 10.3390/ijms232415671. Int J Mol Sci. 2022. PMID: 36555311 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical